Sustainability

When asked what sustainability is, the first thing that comes to people's minds is the environment, especially the conservation of it, like fighting pollution and dealing with waste generation. However, the Brundtland reportThe 1987 UN report Our Common Future, which defined sustainable development. established that sustainability is not only about the environment, and social and economic aspects should also be taken into account. A sustainable solution has to be feasible and equally accessible to all for the three aspects to work together. Thus, this sustainable development page should be read along with Education and Human Practices pages to see how these considerations were integrated throughout our project.

Sustainable development that meets the needs of the present without compromising the ability of future generations to meet their own needs.
UN's Brundtland Commission, report "Our Common Future", 1987

To make sustainable development concrete, the United Nations (UN) adopted the 17 Sustainable Development Goals (SDGs) in 2015 (United Nations Department of Economic and Social Affairs, n.d.). These goals address the major global challenges, ranging from poverty and hunger to clean energy and climate action. The SDGs serve as a roadmap, showing where coordinated international work should be directed to reach a more sustainable world by 2030.

However, the Sustainable Development Goals Report of 2026 shows that just over a third of the SDGs are on track to be achieved by the set deadline. Thus, we wanted to contribute to the SDGs in any way we could, to help bring them closer to reality. This is why we do not only list what our project contributes, but also where it and our team may do harm.

Figure 1. Photograph of the Lund University main building.

For iGEM Lund, sustainability was a priority from the start. We represent Lund University, which ranks first globally in the QS Sustainability RankingsA yearly global ranking of universities by their sustainability performance. (QS Quacquarelli Symonds, 2026), and we felt a responsibility to align our project with sustainability principles. We also decided to be specific and focused instead of wide and shallow, so we selected five goals.

We built sustainability into every part of our project. This page brings it together in two steps: first, what AnTigone and our team contribute to SDG 3, 4, 5, 12 and 17; then, where they may work against these goals.

SDG Contributions

For each goal we explain why it matters for AnTigone and what we did about it.

"Ensure healthy lives and promote well-being for all at all ages"

This goal focuses on ensuring good health and promoting well-being for everyone, at all ages. Of the many targets under this goal, targets 3.4"By 2030, reduce by one third premature mortality from non-communicable diseases through prevention and treatment and promote mental health and well-being", 3.7"By 2030, ensure universal access to sexual and reproductive health-care services, including for family planning, information and education, and the integration of reproductive health into national strategies and programmes" and 3.8"Achieve universal health coverage, including financial risk protection, access to quality essential health-care services and access to safe, effective, quality and affordable essential medicines and vaccines for all" (United Nations Department of Economic and Social Affairs, n.d.) tie in with the project: our potential product and project activities aim to promote mental health, ensure universal access to reproductive services, and provide better access to essential health-care services and to safe, effective, quality and affordable essential medicines for all.

Target 3.4 addresses the reduction of premature mortality from non-communicable diseasesDiseases that do not spread from person to person, such as diabetes and heart disease. and the promotion of mental health and well-being. This is of relevance to us as the mental health burden in PMOS is considerable. Women with the condition have around four times the odds of depressive symptoms and more than five times the odds of anxiety symptoms, when compared to controls (Cooney et al., 2017). International guidelines therefore recommend that every patient is screened for both conditions (Teede et al., 2023). 

Target 3.7 addresses universal access to sexual and reproductive health-care services. PMOS is the most common cause of anovulatory infertilityRelease of egg from the ovaries does not occur, often due to hormonal imbalances. and is also a leading reason for women seeking fertility care (Teede et al., 2023). 

Target 3.8 addresses universal health coverage and access to safe, effective, quality and affordable essential medicines.

"Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all"

This goal focuses on ensuring that quality education and lifelong learning opportunities are available to everyone. Because education is one of our three pillars, we address SDG 4 as a whole, and two of its targets. Target 4.4"By 2030, substantially increase the number of youth and adults who have relevant skills, including technical and vocational skills, for employment, decent jobs and entrepreneurship" (United Nations Department of Economic and Social Affairs, n.d.) aims to increase the number of youth and adults who have relevant technical and vocational skills. Target 4.7"By 2030, ensure that all learners acquire the knowledge and skills needed to promote sustainable development, including, among others, through education for sustainable development and sustainable lifestyles, human rights, gender equality, promotion of a culture of peace and non-violence, global citizenship and appreciation of cultural diversity and of culture’s contribution to sustainable development" (United Nations Department of Economic and Social Affairs, n.d.) aims to ensure that all learners know how and are able to promote sustainable development, like through education for sustainable development, sustainable lifestyles, and, among others, gender equality.

"Achieve gender equality and empower all women and girls"

Goal 5 broadly addresses gender inequality and target 5.6"Ensure universal access to sexual and reproductive health and reproductive rights as agreed in accordance with the Programme of Action of the International Conference on Population and Development and the Beijing Platform for Action and the outcome documents of their review conferences" (United Nations Department of Economic and Social Affairs, n.d.) specifically focuses on achieving universal access to sexual and reproductive health and reproductive rights, giving women the autonomy to make their own informed decisions regarding their reproductive health care. This fits our work partly: PMOS is an endocrine and reproductive condition, and our awareness work supports informed decisions and earlier diagnosis. We do not claim to change access to care itself.

"Ensure sustainable consumption and production patterns"

Goal 12 focuses on producing and consuming within environmental limits. It covers the efficient use of resources, the responsible management of chemicals and waste across their whole life cycle and also the provision of the information people need in order to make sustainable choices. 

The indicators for target 12.4"By 2020, achieve the environmentally sound management of chemicals and all wastes throughout their life cycle, in accordance with agreed international frameworks, and significantly reduce their release to air, water and soil in order to minimize their adverse impacts on human health and the environment" focuses on tracking countries' compliance with international agreements, the hazardous waste generated per capita and the proportion properly treated. Target 12.5"By 2030, substantially reduce waste generation through prevention, reduction, recycling and reuse" focuses on reducing the wastes generated by systematically preventing, reducing, recycling and reusing whenever and wherever possible. Target 12.8"By 2030, ensure that people everywhere have the relevant information and awareness for sustainable development and lifestyles in harmony with nature" focuses on ensuring that people everywhere have the relevant information and awareness for sustainable development and lifestyles grounded in harmony with nature (United Nations Department of Economic and Social Affairs, n.d.).

"Strengthen the means of implementation and revitalize the Global Partnership for Sustainable Development"

Goal 17 recognizes that none of the other goals can be reached by any single actor working on its own. It is concerned with the finance, the technology, the capacity building, the trade and the partnership arrangements which make the rest of the agenda possible. The target 17.17"Encourage and promote effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships " (United Nations Department of Economic and Social Affairs, n.d.) focuses on promoting effective public, public-private and civil society partnerships, building on the experience and resourcing strategies of partnerships (SDG 17).

SDG Inflictions

We took this approach from our meeting with Magdalena Nour (Vati of Sweden), who advised us not to avoid every negative impact but to be conscious about them, explain why they happen and be transparent.

Transparency is the currency. Transparency is what you should focus on.
Magdalena Nour, CEO of Vati of Sweden, in conversation with iGEM Lund, 8 September 2026

We therefore name where our team and our product may work against the goals, why we accept it, and what we do about it. The first group comes from how we as a team work, the second from a hypothetical product.

Team-Based Inflictions

These impacts come from how we, as a student team, run our project: where we teach, how we work in the lab, and how we travel.

Education Reach

Inflicting SDG 4: “Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all.”

SDG 4 asks for inclusive and equitable quality education.

Our reach has stayed narrow in geography, language and audience. Our events took place in Lund (BioCamp, two gymnasium workshops, PMOS Awareness Month, the K-Guild Study Night and the sustainability lecture), in Strängnäs (Rays for Excellence) and in Malmö (library). Most materials are English-only, the podcast is on Spotify, which is not accessible everywhere, and most participants were students already in science programs. We did not measure lasting learning.


This is how we are dealing with it:

  • English is our primary and mostly only language. That is a limitation, but simultaneously also the most inclusive way. We introduced more languages for the material that mattered most, children's books, but besides that we did not further focus on having multiple translations, but we would call that defensible. 
  • Our children's book exists in six languages, Chinese, Spanish, German, Swedish, English, and Italian, genuinely global reach for that specific material, not just an English product.
  • Our podcast, The Sequence, is built specifically to pull in perspectives from outside our own bubble: we've talked with other iGEM teams from e.g. Brazil, Canada, Mexico, Taiwan, and India about their projects, struggles, and journeys. Spotify itself has accessibility limits, but the content is deliberately not Sweden- or Europe-only.
  • The concentration around Lund is partly a deliberate choice, not only a gap: as a small student team, we can have a real, measurable effect on the community immediately around us in a way we couldn't replicate by spreading thin across a global audience we don't have the capacity to actually serve. We think it's more honest to say we chose local depth over global breadth than to claim we achieved both.

Why we accept it: spreading the same effort across many places would have meant less quality everywhere.

Wet Lab Safety

Inflicting SDG 8.8: “Protect labor rights and promote safe and secure working environments for all workers […]”

SDG 8.8"Protect labour rights and promote safe and secure working environments for all workers, including migrant workers, in particular women migrants, and those in precarious employment" (United Nations Department of Economic and Social Affairs, n.d.) calls for safe and secure working environments for all workers. Our wet lab work carries real risk: chemical handling, biological materials, live engineered organisms, testosterone (a controlled steroid hormone), and machinery like UV light and the autoclave.


How we're dealing with it:

The training content, waste handling, equipment and all risk assessments are on our Lab Safety page. The safety of the engineered bacteria themselves is on Biosafety: in-host control, environmental biocontainment and GMO regulations.

Why we accept it: the enzymes had to be tested in a wet lab, but the risks were reduced with the actions above.

Travel & Climate

Inflicting SDG 13: “Take urgent action to combat climate change and its impacts.”

SDG 13 aims to “take urgent action to combat climate change and its impacts” (United Nations Department of Economic and Social Affairs, n.d.). Flying to iGEM meet-ups has a real footprint that adds to human-made climate change. Six of us flew to Málaga via Gdańsk and fourteen will fly from Copenhagen to Paris, about 14.6 t CO₂eCarbon dioxide equivalents in total (myclimate, n.d.-b). For perspective, 1.5 °C-aligned lifestyles target around 2.5 to 3.2 t CO₂e per person for an entire year by 2030 (Koide et al., 2021). One round trip to Málaga via Gdańsk already causes about 1.25 t per traveller. We accept this because staying away would mean missing key parts of the iGEM experience.

Table 1. Estimated flight emissions and offset prices. CPH = Copenhagen, AGP = Málaga, GDN = Gdańsk, CDG = Paris Charles de Gaulle; t CO₂e = tonnes of carbon dioxide equivalent.
GroupFlightsTravellerst CO₂eOffset price (EUR)
MálagaCPH to AGP via GDN, round trip; ~6,100 km45.0131
MálagaCPH to AGP via GDN, one way; ~3,000 km21.233
MálagaAGP to CPH, one way; ~2,500 km20.87623
ParisCPH to CDG, round trip; ~2,000 km147.5197
Total~14.6384

How we're dealing with it:

We calculated the emissions with the myclimate flight calculator and entered the airports, trip type, class and number of passengers (myclimate, n.d.-b). We used the website since it is transparent about its calculation principles (myclimate, n.d.-a). myclimate prices our flights at 384 EUR (~26 EUR per tonne). Tropica Verde uses ~25.7 EUR per tonne, the 2019 EU emissions-trading price, which gives 375 EUR (Tropica Verde e.V., n.d.). We rounded up to 390 EUR for our donation.

The usual answer to flight emissions is carbon offsetsPaying for projects that cut emissions elsewhere to balance one's own emissions., after which the buyer then treats their emissions as canceled.

We did not want to just cancel out our flights and fund a single small project. We wanted to see which options could have a large impact, also for the future. Charities differ enormously in what a euro achieves, and public information on their impact is often incomplete (GiveWell, n.d.). In global health, the least effective HIV/AIDS intervention delivers under 0.1% of the value of the most effective (Ord, 2013). So we looked for organizations that show evidence, cost-effectiveness, room for more funding and transparency (GiveWell, n.d.), and that were researched independently.

Giving Green is an independent research organization for climate giving. Its researchers evaluate nonprofits in depth, publish their remaining uncertainties and accept no funding from the nonprofits they evaluate. It focuses on systemic change through policy, technology and market transformation, and estimates that donations to its top nonprofits are an order of magnitude more effective than the best direct emissions-reduction projects, such as offsets (Giving Green, n.d.-a).

We chose from Giving Green's 2025–2026 list of five top climate nonprofits (Giving Green, n.d.-c). Opportunity Green is a UK-registered charity that works on emissions from aviationThe design, development, production, operation and use of aircraft. and shipping through EU and international policy, legal action and a coalition for cleaner fuels. Giving Green has recommended it since 2023 (Giving Green, n.d.-b).

On 18 October 2026 we donated £330 (about 390 EUR1 EUR = 0.84 GBP (18 October 2026).) to Opportunity Green.

This is a contribution, not a compensation. Policy work cannot be measured precisely per euro (Giving Green, n.d.-a), so we do not claim that it cancels 14.6 t. We chose it because it is a well-researched way we found to make our money count.

Figure 2. Receipt for our one-time donation of £330 to Opportunity Green on 18 October 2026.

Product-Based Inflictions

These impacts concern the hypothetical product. They describe what could happen if it were ever developed.

Access & Affordability

Inflicting SDG 3.8: “Achieve universal health coverage […] and access to safe, effective, quality and affordable essential medicines and vaccines for all” and SDG 10 (goal level): “Reduce inequality within and among countries.”

Target 3.8 asks for universal health coverage and access to safe, effective, quality and affordable essential medicines. SDG 10 asks for reduced inequality within and among countries. AnTigone could deepen inequality if it were ever developed. A product that needs a diagnosis, a prescription, specialized manufacturing and possibly cold storage first reaches the people who already have the best access to care, and PMOS is under-diagnosed everywhere.


Access: Diagnosis of PMOS depends on health systems, which vary between countries. Globally, 4.6 billion people lack access to essential health services, and women, people living in poverty and people in rural areas report greater difficulty accessing them (World Health Organization, 2025). A product that needs a diagnosis and a prescription therefore first reaches the people who are already diagnosed, who are the people with the best access to care. As a live biotherapeutic, AnTigone would also need manufacturing under strict quality control, storage and distribution conditions that we have not tested (possibly cold chain), and approval under the medicinal and GMOGenetically modified organism. rules of each country.

Affordability: Cost is a major barrier already; in three-quarters of countries with data, medicines account for at least 55% of people's out-of-pocketPaid directly by the patient. health spending, and 2.1 billion people face financial hardship to access care (World Health Organization, 2025). Live biotherapeuticsMedicines made of live microorganisms. have so far been priced as specialty drugsHigh-cost medicines for complex or chronic conditions, often needing special handling.. One course of Vowst, an oral product for recurrent C. difficileClostridioides difficile, a bacterium that causes severe, recurring gut infections, often after antibiotics. infection, has an estimated retail price of $19,500 USD (Smith & Roy, 2024). This treats a different condition, but it shows what price range is possible. Our own target is SEK 300 to 1,000 per month, a suggested range rather than a calculated price, set between generic PMOS drugs and weight-management drugs (See Economical Assessment). Whether insurance would pay depends on national decisions (in Sweden,TLVThe Dental and Pharmaceutical Benefits Agency, which decides which medicines are subsidized in Sweden.), and repeat dosing would raise the cost over time.

How we're dealing with it: we are not claiming access. We explore the oral capsule format, which is easier to store and administer than injections or infusions, and we did a first price estimation and target in the Economical Assessment. We do not know what it would cost to manufacture or distribute.

Why we accept it: AnTigone is a proof of concept, and a student team cannot solve pricing, distribution and regulation.

Environmental & Biocontainment Footprint

Inflicting SDG 12.4: “[…] achieve the environmentally sound management of chemicals and all wastes throughout their life cycle […]” and SDG 6.3: “[…] improve water quality by reducing pollution […]”

Target 12.4 asks for environmentally sound management of chemicals and all wastes, and 6.3"By 2030, improve water quality by reducing pollution, eliminating dumping and minimizing release of hazardous chemicals and materials, halving the proportion of untreated wastewater and substantially increasing recycling and safe reuse globally" (United Nations Department of Economic and Social Affairs, n.d.) asks for better water quality by reducing pollution.

A live engineered organism is different from a chemical drug. If it left the gut, patients could shed it into wastewater, and its genes could in principle spread to other bacteria (horizontal gene transferMovement of genetic information between organisms), which has been shown for engineered gut bacteria in animal experiments (Wegmann et al., 2017). Wild-type E. coli Nissle 1917 stays in the gut for weeks after dosing: in a placebo-controlled study in healthy volunteers, 45 of 48 tested positive during dosing, and many still did 12 weeks after it stopped (Joeres-Nguyen-Xuan et al., 2010). Our design relies on redosing, which means continuous production, packaging and, potentially, cold chain. We have not assessed the footprint of manufacturing, and none of our containment layers has been tested.


How we're dealing with it:

Why we accept it: a live engineered organism is the core of the idea. This is the other side of our SDG 12 claim: if AnTigone replaced hormonal drugs it could reduce hormone discharge (see SDG 12: Responsible Consumption and Production), but it would add a GMO release risk that hormones do not have.

References

  1. Akin, H., Rose, K. M., Scheufele, D. A., Simis-Wilkinson, M., Brossard, D., Xenos, M. A., & Corley, E. A. (2017). Mapping the landscape of public attitudes on synthetic biology. BioScience, 67(3), 290–300. https://doi.org/10.1093/biosci/biw171
  2. Bahri Khomami, M., Shorakae, S., Hashemi, S., Harrison, C. L., Piltonen, T. T., Romualdi, D., Tay, C. T., Teede, H. J., Vanky, E., & Mousa, A. (2024). Systematic review and meta-analysis of pregnancy outcomes in women with polycystic ovary syndrome. Nature Communications, 15(1), Article 5591. https://doi.org/10.1038/s41467-024-49749-1
  3. Barlek, M. H., Rouan, J. R., Wyatt, T. G., Helenowski, I., & Kibbe, M. R. (2022). The persistence of sex bias in high-impact clinical research. Journal of Surgical Research, 278, 364–374. https://doi.org/10.1016/j.jss.2022.04.077
  4. Cooney, L. G., Lee, I., Sammel, M. D., & Dokras, A. (2017). High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: A systematic review and meta-analysis. Human Reproduction, 32(5), 1075–1091. https://doi.org/10.1093/humrep/dex044
  5. European Medicines Agency. (2006). Guideline on environmental risk assessments for medicinal products consisting of, or containing, genetically modified organisms (GMOs) (EMEA/CHMP/BWP/473191/2006 - Corr). https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-environmental-risk-assessments-medicinal-products-consisting-or-containing-genetically-modified-organisms-gmos_en.pdf
  6. European Parliament and Council of the European Union. (2001). Directive 2001/18/EC on the deliberate release into the environment of genetically modified organisms and repealing Council Directive 90/220/EEC. Official Journal of the European Communities, L 106, 1–39. https://eur-lex.europa.eu/eli/dir/2001/18/oj
  7. European Parliament and Council of the European Union. (2001). Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official Journal of the European Communities, L 311, 67–128. https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32001L0083
  8. European Parliament and Council of the European Union. (2009). Directive 2009/41/EC on the contained use of genetically modified micro-organisms. Official Journal of the European Union, L 125, 75–97. https://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=OJ:L:2009:125:0075:0097:EN:PDF
  9. Forslund, M., Melin, J., Joham, A. E., Piltonen, T. T., Rees, D. A., & Teede, H. J. (2026). Recent advances in polyendocrine metabolic ovarian syndrome, formerly polycystic ovary syndrome, with emphasis on endocrine and metabolic dysfunction and cardiovascular risk. Journal of Internal Medicine. Advance online publication. https://doi.org/10.1111/joim.70156
  10. Gibson-Helm, M., Teede, H., Dunaif, A., & Dokras, A. (2017). Delayed diagnosis and a lack of information associated with dissatisfaction in women with polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 102(2), 604–612. https://doi.org/10.1210/jc.2016-2963
  11. GiveWell. (n.d.). Our criteria. Retrieved October 17, 2026, from https://www.givewell.org/how-we-work/criteria
  12. Giving Green. (n.d.-a). Frequently asked questions. Retrieved October 17, 2026, from https://www.givinggreen.earth/faq
  13. Giving Green. (n.d.-b). Opportunity Green: Top climate nonprofit spotlight. Retrieved October 17, 2026, from https://www.givinggreen.earth/research/opportunity-green-top-climate-nonprofit-spotlight
  14. Giving Green. (n.d.-c). Top climate nonprofits. Retrieved October 17, 2026, from https://www.givinggreen.earth/top-climate-nonprofits
  15. Joeres-Nguyen-Xuan, T. H., Boehm, S. K., Joeres, L., Schulze, J., & Kruis, W. (2010). Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers. Inflammatory Bowel Diseases, 16(2), 256–262. https://doi.org/10.1002/ibd.21042
  16. Kemicentrum. (n.d.). General safety regulations. Lund University. Retrieved October 11, 2026, from https://www.kc.lu.se/en/employee/general-safety-regulations
  17. Kidd, K. A., Blanchfield, P. J., Mills, K. H., Palace, V. P., Evans, R. E., Lazorchak, J. M., & Flick, R. W. (2007). Collapse of a fish population after exposure to a synthetic estrogen. Proceedings of the National Academy of Sciences, 104(21), 8897–8901. https://doi.org/10.1073/pnas.0609568104
  18. Klaica, M., & Jirsa, F. (2022). 17α-Ethinylestradiol (EE2): Concentrations in the environment and methods for wastewater treatment – An update. RSC Advances, 12(20), 12794–12805. https://doi.org/10.1039/D2RA00915C
  19. Koide, R., Lettenmeier, M., Akenji, L., Toivio, V., Amellina, A., Khodke, A., Watabe, A., & Kojima, S. (2021). Lifestyle carbon footprints and changes in lifestyles to limit global warming to 1.5 °C, and ways forward for related research. Sustainability Science, 16(6), 2087–2099. https://doi.org/10.1007/s11625-021-01018-6
  20. Liu, J., Zhang, Y., Huang, Y., Li, X., Huang, X., Xing, X.-H., & Zhang, C. Y. (2026). Enabling clinical translation of oral probiotics through formulation engineering and scalable manufacturing. Biotechnology Journal, 21(6), Article e70253. https://doi.org/10.1002/biot.70253
  21. myclimate. (n.d.-a). Calculation principles: Flight emissions calculator. Retrieved October 17, 2026, from https://www.myclimate.org/en/information/about-myclimate/downloads/flight-emission-calculator/
  22. myclimate. (n.d.-b). Flight emissions calculator. Retrieved October 17, 2026, from https://co2.myclimate.org/en/flight_calculators/new
  23. Ord, T. (2013). The moral imperative toward cost-effectiveness in global health. Center for Global Development. https://www.cgdev.org/publication/moral-imperative-toward-cost-effectiveness-global-health
  24. Panchpuri, M., Kisku, A., Painuli, R., Pant, G., & Kumar, C. (2026). Polycystic ovary syndrome (PCOS): Current insights, emerging therapeutics, and future treatment strategies. Inflammopharmacology, 34(2), 1005–1040. https://doi.org/10.1007/s10787-026-02117-5
  25. QS Quacquarelli Symonds. (2026). QS Sustainability Rankings 2026. Top Universities. Retrieved September 21, 2026, from https://www.topuniversities.com/sustainability-rankings
  26. Smith, A., & Roy, T. (2024). Fecal microbiota spores, live-brpk (Vowst) to prevent Clostridioides difficile infection. American Family Physician, 109(5), 472–473. https://www.aafp.org/afp/2024/0500/steps-clostridioides-difficile-infection
  27. Teede, H. J., Khomami, M. B., Morman, R., Laven, J. S. E., Joham, A. E., Costello, M. F., Patil, M., Rees, D. A., Berry, L., Cree, M. G., Zhao, H., Norman, R. J., Dokras, A., Piltonen, T., Amao, S., Amiri, M., Andrews, C., Arcari, A., Arlt, W., . . . Zhang, Y. (2026). Polyendocrine metabolic ovarian syndrome, the new name for polycystic ovary syndrome: A multistep global consensus process. The Lancet, 407(10545), 2329–2339. https://doi.org/10.1016/s0140-6736(26)00717-8
  28. Teede, H. J., Tay, C. T., Laven, J. J. E., Dokras, A., Moran, L. J., Piltonen, T. T., Costello, M. F., Boivin, J., Redman, L. M., Boyle, J. A., Norman, R. J., Mousa, A., & Joham, A. E. (2023). Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. The Journal of Clinical Endocrinology & Metabolism, 108(10), 2447–2469. https://doi.org/10.1210/clinem/dgad463
  29. Tropica Verde e.V. (n.d.). CO2 compensation. Retrieved October 17, 2026, from https://tropica-verde.de/en/help-donate/co2-kompensation/
  30. United Nations Department of Economic and Social Affairs. (n.d.). The 17 goals. Retrieved October 1, 2026, from https://sdgs.un.org/goals
  31. Wegmann, U., Carvalho, A. L., Stocks, M., & Carding, S. R. (2017). Use of genetically modified bacteria for drug delivery in humans: Revisiting the safety aspect. Scientific Reports, 7, Article 2294. https://doi.org/10.1038/s41598-017-02591-6
  32. Wilkinson, J. L., Boxall, A. B. A., Kolpin, D. W., Leung, K. M. Y., Lai, R. W. S., Galbán-Malagón, C., Adell, A. D., Mondon, J., Metian, M., Marchant, R. A., Bouzas-Monroy, A., Cuni-Sanchez, A., Coors, A., Carriquiriborde, P., Rojo, M., Gordon, C., Cara, M., Moermond, M., Luarte, T., . . . Teta, C. (2022). Pharmaceutical pollution of the world's rivers. Proceedings of the National Academy of Sciences, 119(8), Article e2113947119. https://doi.org/10.1073/pnas.2113947119
  33. World Health Organization. (2025, December 6). Most countries make progress towards universal health coverage, but major challenges remain, WHO–World Bank report finds [News release]. https://www.who.int/news/item/06-12-2025-most-countries-make-progress-towards-universal-health-coverage-but-major-challenges-remain-who-world-bank-report-finds
  34. World Health Organization. (2026, January 22). Polycystic ovary syndrome [Fact sheet]. https://www.who.int/news-room/fact-sheets/detail/polycystic-ovary-syndrome